Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

BACKGROUND: Previous randomized studies have demonstrated that fesoterodine significantly improves the Overactive Bladder (OAB) symptoms and their assessment by patients compared with tolterodine extended-release (ER). This study aimed to assess the effect of aging and dose escalation on patient-rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro-Diaz, David, Miranda, Pilar, Sanchez-Ballester, Francisco, Lizarraga, Isabel, Arumí, Daniel, Rejas, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514115/
https://www.ncbi.nlm.nih.gov/pubmed/22834707
http://dx.doi.org/10.1186/1471-2490-12-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514115/
https://www.ncbi.nlm.nih.gov/pubmed/22834707
http://dx.doi.org/10.1186/1471-2490-12-19

Ejemplares similares